Clinical Studies

This clinical trial aims to evaluate the efficacy and safety of an investigational veterinary drug delivered by skin injection for itching and inflammation associated with atopic skin syndrome in cats.

A new veterinary device composed of collagen and elastin particles has been developed; it has been shown to help protect cartilage from mechanical grinding. Previous anecdotal use of this product has been beneficial in dogs with elbow dysplasia.

We are studying a novel live probiotic product typically found in the gut of healthy dogs to evaluate the ability of this probiotic to resolve diarrhea in dogs.

This study will evaluate the safety and effectiveness of a newly proposed anti-inflammatory drug in dogs experiencing mild acute onset pancreatitis (AOP) symptoms.

Xylitol is an artificial sweetener commonly found in sugar-free gum. Although safe for humans, xylitol is highly toxic to dogs. This study will compare the liver protective capacity of two veterinary liver protectant products in dogs suffering from xylitol toxicity.

This clinical trial will evaluate the effectiveness of a novel investigational product for the treatment of oral melanoma in dogs.

This study aims to determine whether or not canine patients diagnosed with canine osteosarcoma (OSA) have intestinal dysbiosis and whether treating intestinal disease improves patient outcomes.

Is your dog undergoing surgery for a ruptured splenic tumor? Ethos Discovery would love to have you and your dog participate in our clinical trial! We are evaluating drugs for the treatment of HSA with the goal of curing this aggressive cancer.

A new veterinary device composed of collagen and elastin particles has been developed; it is delivered via intra-articular injection and helps protect cartilage from mechanical grinding. This study seeks to validate this device as a pre-surgical management tool for dogs with cruciate disease.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

This is an exploratory study to evaluate the safety and effectiveness of concomitant intraarticular (IA) and peri-neural (PN) injections of an investigational veterinary product for the control of elbow pain in dogs. This 28-day study also includes a long term follow up at 3 and 6 months.

Despite years of active research in the field, high mortality rates associated with sepsis have remained unchanged over the last three decades; we aim to change this!